SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes pre-approval inspection at Biocon’s Malaysia facility

21 Feb 2018 Evaluate

The US Food and Drug Administration (USFDA) has completed a pre-approval inspection at Biocon’s manufacturing facility in Malaysia and issued a Form 483 with 6 observations. The company intends to respond with a corrective and preventive action plan in a timely manner.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.



Biocon Share Price

384.45 3.70 (0.97%)
07-May-2026 12:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.80
Dr. Reddys Lab 1309.95
Cipla 1374.15
Zydus Lifesciences 941.40
Lupin 2469.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×